Catalyst Pharmaceutical Partners Company Profile (NASDAQ:CPRX)

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Industry, Sector and Symbol:

Sector: Medical
Industry: Drugs - Generic
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: CPRX
CUSIP:

Key Metrics:

Previous Close: $1.17
50 Day Moving Average: $0.98
200 Day Moving Average: $0.88
52-Week Range: $0.51 - $3.60
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -4.18
P/E Growth: 0.00
Market Cap: $96.96M
Outstanding Shares: 82,870,000
Beta: 0.94

Profitability:

Return on Equity: -41.35%
Return on Assets: -38.75%

Debt:

Current Ratio: 21.16%
Quick Ratio: 21.16%

Additional Links:

Companies Related to Catalyst Pharmaceutical Partners:

Consensus Ratings for Catalyst Pharmaceutical Partners (NASDAQ:CPRX) (?)

Ratings Breakdown:	1 Hold Rating, 3 Buy Ratings
Consensus Rating:	Buy (Score: 2.75)
Consensus Price Target:	$3.42 (192.02% upside)

Analysts' Ratings History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)

Show:

Date	Firm	Action	Rating	Price Target
6/14/2016	HC Wainwright	Reiterated Rating	Buy
4/26/2016	Piper Jaffray Cos.	Downgrade	Overweight -> Neutral	$6.00 -> $1.00
3/22/2016	Roth Capital	Reiterated Rating	Buy
2/20/2016	SunTrust Banks Inc.	Reiterated Rating	Buy	$7.00 -> $6.00
6/24/2015	MLV & Co.	Initiated Coverage	Buy	$14.00
10/1/2014	Aegis	Boost Price Target	Positive	$7.00

(Data available from 9/28/2014 forward)

Earnings History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
11/7/2016
8/9/2016	Q216	($0.08)	($0.06)	View	N/A
5/10/2016	Q116	($0.07)	($0.07)	View	N/A
3/15/2016	Q415	($0.07)	($0.07)	View	N/A
11/9/2015	Q315	($0.07)	($0.05)	View	N/A
8/10/2015	Q215	($0.08)	($0.06)	View	Listen
5/11/2015	Q115	($0.09)	($0.06)	View	N/A
3/16/2015	Q414	($0.07)	($0.06)	View	N/A
11/14/2014	Q314	($0.05)	($0.06)	View	N/A
8/14/2014	Q214	($0.07)	($0.05)	View	N/A
5/16/2014	Q114	($0.06)	($0.07)	View	N/A
3/19/2014	Q413	($0.07)	($0.02)	View	N/A
11/14/2013	Q3	($0.07)	($0.07)	View	N/A
8/15/2013	Q213	($0.07)	($0.06)	View	N/A
11/15/2012	Q312		($0.08)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)

Current Year EPS Consensus Estimate: $-0.27 EPS
Next Year EPS Consensus Estimate: $-0.28 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	($0.06)	($0.06)	($0.06)
Q2 2016	1	($0.06)	($0.06)	($0.06)
Q3 2016	2	($0.06)	($0.06)	($0.06)
Q4 2016	2	($0.08)	($0.07)	($0.08)

(Data provided by Zacks Investment Research)

Dividend History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)

Insider Ownership Percentage: 8.79%
Institutional Ownership Percentage: 30.64%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
7/12/2016	Charles B O'keeffe	Director	Buy	20,000	$0.81	$16,200.00
6/17/2016	Philip H Coelho	Director	Buy	15,000	$0.76	$11,400.00
6/14/2016	Donald A Denkhaus	Director	Buy	50,000	$0.65	$32,500.00
6/14/2016	Patrick J Mcenany	CEO	Buy	105,300	$0.65	$68,445.00
4/26/2016	Charles B O'keeffe	Director	Buy	20,000	$0.60	$12,000.00
4/26/2016	Patrick J Mcenany	CEO	Buy	50,000	$0.65	$32,500.00
3/17/2016	Philip H Coelho	Director	Buy	10,000	$1.06	$10,600.00
3/16/2016	Charles B O'keeffe	Director	Buy	10,000	$1.11	$11,100.00
1/11/2016	Steve Miller	COO	Buy	7,933	$1.80	$14,279.40
1/8/2016	Charles B O'keeffe	Director	Buy	5,000	$1.94	$9,700.00
1/7/2016	Donald A Denkhaus	Director	Buy	25,000	$2.03	$50,750.00
12/28/2015	Patrick J Mcenany	CEO	Buy	25,000	$2.39	$59,750.00
12/23/2015	Charles B O'keeffe	Director	Buy	5,000	$2.41	$12,050.00
11/19/2015	Charles B O'keeffe	Director	Buy	5,000	$2.30	$11,500.00
10/23/2015	M Douglas Winship	VP	Sell	22,800	$3.34	$76,152.00
10/1/2015	Patrick J Mcenany	CEO	Buy	10,000	$2.81	$28,100.00
5/1/2015	David D Muth	EVP	Buy	1,700	$3.20	$5,440.00
4/30/2015	Charles B O'keeffe	Director	Buy	10,000	$3.29	$32,900.00
4/28/2015	David D Muth	EVP	Buy	2,000	$3.55	$7,100.00
4/27/2015	Donald A Denkhaus	Director	Buy	15,000	$3.71	$55,650.00
4/27/2015	Patrick J Mcenany	CEO	Buy	5,000	$3.79	$18,950.00
4/24/2015	Charles B O'keeffe	Director	Buy	5,000	$3.80	$19,000.00
3/27/2015	Donald A Denkhaus	Director	Buy	5,000	$4.17	$20,850.00
1/20/2015	David D Muth	EVP	Buy	21,000	$2.96	$62,160.00
1/13/2015	Charles B O'keeffe	Director	Buy	10,000	$3.00	$30,000.00
1/8/2015	Patrick J Mcenany	CEO	Buy	50,000	$2.80	$140,000.00
10/3/2014	David D Muth	VP	Buy	10,000	$2.65	$26,500.00
6/4/2014	Steve Miller	COO	Buy	100,000	$2.17	$217,000.00
5/21/2014	Patrick Mcenany	CEO	Buy	25,000	$1.89	$47,250.00
5/19/2014	Charles O'keeffe	Director	Buy	10,000	$1.83	$18,300.00
4/16/2014	Charles O'keeffe	Director	Buy	5,000	$2.02	$10,100.00
2/7/2014	Patrick Mcenany	CEO	Buy	25,000	$1.82	$45,500.00
2/5/2014	Charles O'keeffe	Director	Buy	10,000	$1.81	$18,100.00
10/23/2013	David S Tierney	Director	Buy	8,000	$2.03	$16,240.00
10/21/2013	Charles B O'keeffe	Director	Buy	10,000	$1.84	$18,400.00
10/21/2013	Patrick J Mcenany	CEO	Buy	50,000	$1.59	$79,500.00
2/19/2013	Patrick J Mcenany	CEO	Buy	50,000	$0.46	$23,000.00
12/17/2012	Patrick J Mcenany	CEO	Buy	100,000	$0.45	$45,000.00
12/8/2012	Biomarin Pharmaceutical Inc	Major Shareholder	Buy	5,000,000	$0.75	$3,750,000.00
11/15/2012	Patrick J Mcenany	CEO	Buy	100,000	$0.42	$42,000.00
11/15/2012	Philip H Coelho	Director	Buy	24,000	$0.41	$9,840.00

(Data available from 1/1/2013 forward)

Latest Headlines for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)

Date	Headline
	Stocks Ringing Investment Alarms: Microsoft (NASDAQ:MSFT ... - Street Wise Report (press release) (blog) (NASDAQ:CPRX) streetwisereport.com - September 23 at 9:31 AM
	Under the Microscope, Zeroing in at Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Duncan Research (NASDAQ:CPRX) www.duncanindependent.com - September 23 at 9:31 AM
	Catalyst Pharmaceuticals, Inc. :CPRX-US: Earnings Analysis: Q2, 2016 By the Numbers : September 21, 2016 (NASDAQ:CPRX) www.capitalcube.com - September 21 at 4:56 PM
	CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, F (NASDAQ:CPRX) biz.yahoo.com - September 20 at 10:11 AM
	Catalyst Pharmaceuticals Announces Publication of CPP-115 Clinical Efficacy Data for Infantile Spasms in Epilepsy & Behavior Case Reports (NASDAQ:CPRX) www.publicnow.com - September 19 at 9:04 AM
	Catalyst Pharmaceuticals Announces Launch of Expanded Access Program Website and Participation at the American Association of Neuromuscular & Electrodiagnostic Medicine Conference (NASDAQ:CPRX) finance.yahoo.com - September 14 at 8:42 AM
	Placing Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Shares Under the Microscope - Post News (NASDAQ:CPRX) www.kentuckypostnews.com - September 9 at 4:17 PM
	Stock Perspective: Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Company Earnings Watch - Frisco Fastball (NASDAQ:CPRX) friscofastball.com - September 9 at 4:17 PM
	Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) From The Analysts Point of View - National Daily Press (NASDAQ:CPRX) www.nationaldailypress.com - September 9 at 4:17 PM
	Catalyst Pharmaceuticals to Present at Rodman & Renshaw's 18th Annual Global Investment Conference (NASDAQ:CPRX) www.publicnow.com - September 8 at 4:15 PM
	Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference (NASDAQ:CPRX) finance.yahoo.com - September 8 at 8:07 AM
	What We’re Looking For From The Catalyst Pharmaceuticals Inc (CPRX) Data (NASDAQ:CPRX) www.insidermonkey.com - September 6 at 9:14 AM
	10:40 am Catalyst Pharma confirms that the FDA has granted the company orphan drug designation for Firdapse (NASDAQ:CPRX) finance.yahoo.com - September 5 at 9:02 AM
	Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for the Treatment of Myasthenia Gravis (NASDAQ:CPRX) www.publicnow.com - September 2 at 4:09 PM
	CATALYST PHARMACEUTICALS, INC. Financials (NASDAQ:CPRX) finance.yahoo.com - August 19 at 3:28 PM
	Crowd & Street Monitoring Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Post News (NASDAQ:CPRX) www.kentuckypostnews.com - August 19 at 10:32 AM
	Catalyst Pharmaceuticals (CPRX) Looks Good: Stock Up 6.3% (NASDAQ:CPRX) finance.yahoo.com - August 18 at 10:24 AM
	Catalyst (CPRX) Reports Narrower-than-Expected Q2 Loss (NASDAQ:CPRX) finance.yahoo.com - August 10 at 4:27 PM
	Catalyst reports 2Q loss (NASDAQ:CPRX) sg.finance.yahoo.com - August 10 at 8:04 AM
	Catalyst Pharmaceuticals Announces Second Quarter 2016 Financial Results and Provides Product Development Update (NASDAQ:CPRX) www.publicnow.com - August 9 at 5:22 PM
	Q2 2016 Catalyst Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:CPRX) biz.yahoo.com - August 9 at 10:51 AM
	Catalyst Pharmaceutical Partners, Inc. (CPRX) Updated Price Targets - FTSE News (NASDAQ:CPRX) www.ftsenews.co.uk - August 5 at 9:42 PM
	Catalyst (CPRX) Q2 Earnings: Can the Stock Pull a Surprise? (NASDAQ:CPRX) finance.yahoo.com - August 3 at 10:01 PM
	Catalyst Pharmaceuticals to Hold Second Quarter Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 10th, 2016 (NASDAQ:CPRX) www.publicnow.com - August 1 at 8:31 AM
	New Broker Ratings For Catalyst Pharmaceutical Partners, Inc. (CPRX) - FTSE News (NASDAQ:CPRX) www.ftsenews.co.uk - July 15 at 8:27 PM
	Crowd Rating and Earnings Recap for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Telanagana Press (NASDAQ:CPRX) telanaganapress.com - July 15 at 10:03 AM
	Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:CPRX) telanaganapress.com - July 14 at 8:40 AM
	Noteworthy Insider Transactions at 5 Companies Amid Slowing Insider Buying as Markets Near All-Time Highs (NASDAQ:CPRX) www.insidermonkey.com - July 13 at 12:35 PM
	2016 Q1 Sentiment Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX) - Consumer Eagle (NASDAQ:CPRX) www.consumereagle.com - July 12 at 9:48 PM
	Trading Performance and Target Watch for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Press Telegraph (NASDAQ:CPRX) presstelegraph.com - July 12 at 8:41 AM
	Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:CPRX) www.engelwooddaily.com - July 12 at 8:41 AM
	Next Weeks Broker Price Targets For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Fiscal Standard (NASDAQ:CPRX) www.fiscalstandard.com - July 12 at 8:41 AM
	Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Stock Update: Check on Ratings and Target Price - Telanagana Press (NASDAQ:CPRX) telanaganapress.com - July 7 at 9:37 PM
	Broker Outlook For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Fiscal Standard (NASDAQ:CPRX) www.fiscalstandard.com - July 7 at 9:37 PM
	Stock Rating Watch and Earnings Insight for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Press Telegraph (NASDAQ:CPRX) presstelegraph.com - July 6 at 9:06 AM
	Broker Outlook For The Week Ahead Catalyst Pharmaceutical Partners, Inc. (CPRX) - Fiscal Standard (NASDAQ:CPRX) www.fiscalstandard.com - July 6 at 9:06 AM
	Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Company Rating and Target Watch - Telanagana Press (NASDAQ:CPRX) telanaganapress.com - June 30 at 11:34 AM
	Recently Issued Stock Ratings For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Fiscal Standard (NASDAQ:CPRX) www.fiscalstandard.com - June 30 at 11:34 AM
	Share Update and Earnings Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Press Telegraph (NASDAQ:CPRX) presstelegraph.com - June 29 at 11:40 AM
	Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:CPRX) www.engelwooddaily.com - June 28 at 9:16 AM
	CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an (NASDAQ:CPRX) biz.yahoo.com - June 24 at 5:02 PM
	Can Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Surprise Analysts this Quarter? - Investor Newswire (NASDAQ:CPRX) www.investornewswire.com - June 23 at 3:44 PM
	Catalyst Pharmaceutical Partners, Inc. (CPRX) Current Analyst Ratings - Fiscal Standard (NASDAQ:CPRX) www.fiscalstandard.com - June 22 at 4:32 PM
	CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule (NASDAQ:CPRX) biz.yahoo.com - June 10 at 5:02 PM
	Catalyst Pharmaceuticals, Inc. :CPRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 (NASDAQ:CPRX) www.capitalcube.com - June 10 at 5:02 PM
	CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters t (NASDAQ:CPRX) biz.yahoo.com - June 7 at 4:49 PM
	After Last Week What Do Analysts Think Of Catalyst Pharmaceutical Partners, Inc. (CPRX) - Share Trading News (NASDAQ:CPRX) www.sharetrading.news - June 5 at 9:41 PM
	Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Stock Update & Estimates - Stock Tick Tock (NASDAQ:CPRX) www.stockticktock.com - June 4 at 9:43 PM
	Strong Sell Calls Count For Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) At 0 - Investor Newswire (NASDAQ:CPRX) www.investornewswire.com - June 2 at 10:22 PM
	Stock Review and Earnings Check on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - HNN (NASDAQ:CPRX) hintsnewsnetwork.com - June 1 at 12:34 PM